iifl-logo

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

sidebar image

Gland Pharma Gets USFDA Nod for Angiotensin II Injection

15 Nov 2023 , 01:06 PM

Gland Pharma Limited secures tentative approval from the USFDA for Angiotensin II Injection, 2.5 mg/mL Single Dose Vial. The company claims to be the first to file for this product, anticipating eligibility for 180 days of generic drug exclusivity.

Gland Pharma plans to launch the product in collaboration with its marketing partner upon final approval. Angiotensin II is prescribed to increase blood pressure in adult patients, addressing low blood pressure with septic shock or distributive shock.

The approved product, Angiotensin II Injection, 2.5 mg/mL Single Dose Vial (RLD: Giapreza Injection), recorded US sales of approximately USD 38 million for the twelve months ending in September 2023, according to IQVIA.

In the July-September quarter, Gland Pharma reports a 19.56% YoY decline in consolidated net profit, amounting to Rs 194 crore. However, the company’s revenue shows a positive trend, reaching Rs 1,373.4 crore, a 31.52% increase from the year-ago quarter’s figure of Rs 1,044.4 crore.

For feedback and suggestions, write to us at editorial@iifl.com

 

Related Tags

  • Gland Pharma
  • Gland Pharma IPO
  • Gland Pharma news
  • Gland Pharma share price
  • Gland Pharma USFDA
sidebar mobile

BLOGS AND PERSONAL FINANCE

Read More

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.